Phathom Pharmaceuticals, Inc.
PHAT
$4.41
$0.194.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.66M | 16.35M | 7.32M | 1.91M | 682.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.66M | 16.35M | 7.32M | 1.91M | 682.00K |
| Cost of Revenue | 3.82M | 2.36M | 1.38M | 426.00K | 167.00K |
| Gross Profit | 25.85M | 14.00M | 5.95M | 1.49M | 515.00K |
| SG&A Expenses | 76.68M | 76.10M | 75.87M | 62.01M | 57.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.08M | 87.15M | 84.62M | 71.87M | 70.56M |
| Operating Income | -59.42M | -70.80M | -77.30M | -69.95M | -69.88M |
| Income Before Tax | -74.45M | -85.58M | -91.45M | -82.85M | -79.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.45M | -85.58M | -91.45M | -82.85M | -79.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.45M | -85.58M | -91.45M | -82.85M | -79.57M |
| EBIT | -59.42M | -70.80M | -77.30M | -69.95M | -69.88M |
| EBITDA | -59.22M | -70.61M | -77.10M | -69.74M | -69.69M |
| EPS Basic | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 |
| Normalized Basic EPS | -0.66 | -0.83 | -0.98 | -0.89 | -0.87 |
| EPS Diluted | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 |
| Normalized Diluted EPS | -0.66 | -0.83 | -0.98 | -0.89 | -0.87 |
| Average Basic Shares Outstanding | 71.04M | 64.63M | 58.56M | 58.37M | 57.29M |
| Average Diluted Shares Outstanding | 71.04M | 64.63M | 58.56M | 58.37M | 57.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
